Infection Control

Singapore

Infection Control

Singapore
SEARCH FILTERS
Time filter
Source Type

Net Income Increased 8.5% as a Result of Continued Focus on Management of Product Alpha Pro Tech, Ltd. ( : APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced financial results for the quarter ended March 31, 2017. Lloyd Hoffman, CEO of Alpha Pro Tech, commented, "Our earnings increased year-over-year as a result of our continued efforts to reduce product costs while controlling operating expenses, despite a softness in Building Supply sales, particularly in our synthetic roof underlayment line of products. A corporate mandate from one of our large distributors to lower inventory levels was a significant driver of lower sales in the Building Supply segment for the quarter. We expect that Building Supply segment sales will accelerate in the latter half of 2017 and may reach record levels." "We further reduced inventory levels by another 3% compared to year-end 2016 in an effort to further improve efficiencies in our operations, optimize the use of capital and generate positive cash from operations to support our share repurchase program," concluded Hoffman. Net sales Consolidated sales for the first quarter of 2017 were $10.8 million, compared to $11.8 million in the first quarter of 2016. Building Supply segment sales for the three months ended March 31, 2017 decreased by 12.1% to $5.9 million, compared to $6.8 million for the same period of 2016. The sales mix of the Building Supply segment for the three months ended March 31, 2017 was 54% for synthetic roof underlayment, 41% for housewrap and 5% for other woven material. This compared to 63% for synthetic roof underlayment, 33% for housewrap and 4% for other woven material for the first quarter of 2016. Sales for the Disposable Protective Apparel segment for the three months ended March 31, 2017 decreased 13.9% to $3.3 million, compared to $3.8 million for the same period of 2016. Infection Control segment sales for the three months ended March 31, 2017 increased by $249,000, or 19.6%, to $1.5 million, compared to $1.3 million for the same period of 2016. Gross profit Gross profit for the first quarter of 2017 increased by 1.2% to $4.3 million, or 39.9% gross profit margin, compared to $4.2 million, or 35.8% gross profit margin, for the same period of 2016. Selling, general and administrative expenses Selling, general and administrative expenses of $3.5 million for the first quarter of 2017 were essentially unchanged from the same period of 2016. As a percentage of net sales, selling, general and administrative expenses increased to 32.3% for the first quarter ended March 31, 2017, up from 29.2% for the same period of 2016. Net income Net income increased for the first quarter of 2017 to $550,000, compared to $507,000 for the same period of 2016, an increase of $43,000, or 8.5%. Net income as a percentage of net sales for the first quarter of 2017 and 2016 was 5.1% and 4.3%, respectively. Basic and diluted earnings per common share for the first quarters of 2017 and 2016 were $0.04 and $0.03, respectively. Balance Sheet The consolidated balance sheet remained strong with a cash balance of $7.9 million as of March 31, 2017, a decrease of $1.6 million from $9.5 million as of December 31, 2016. The change in cash position was due to cash provided by operating activities of $162,000, offset by cash used in investing activities of $584,000 and cash used in financing activities, solely the repurchase of our common stock, of $1.2 million. The Company ended the quarter with working capital of $25.6 million and a current ratio of 14:1, compared to a 12:1 current ratio as of December 31, 2016. Inventory decreased by $315,000, or 2.9%, to $10.7 million as of March 31, 2017 from $11.0 million as of December 31, 2016. The decrease was primarily due to a decrease in inventory for the Disposable Protective Apparel segment of $612,000, or 16.4%, to $3.1 million, and a decrease in inventory for the Infection Control segment of $123,000, or 5.3%, to $2.2 million, partially offset by an increase in inventory for the Building Supply segment of $420,000, or 8.6%, to $5.3 million. Colleen McDonald, Chief Financial Officer, commented, "At the end of the quarter, we had $1.4 million available for additional stock purchases under our stock repurchase program. During the quarter we repurchased 362,700 shares of common stock at a cost of $1.2 million, bringing the program total to 15,334,231 shares of common stock at a cost of $26.2 million since the program's inception. All stock is retired upon repurchase, and future repurchases are expected to be funded from cash on hand and cash flows from operating activities." The Company currently has no outstanding debt and maintains an unused $3.5 million credit facility. The Company believes that current cash balances and the borrowings available under its credit facility will be sufficient to satisfy projected working capital needs and planned capital expenditures for the foreseeable future. About Alpha Pro Tech, Ltd. Alpha Pro Tech, Ltd. is the parent company of Alpha Pro Tech, Inc. and Alpha ProTech Engineered Products, Inc. Alpha Pro Tech, Inc. develops, manufactures and markets innovative disposable and limited-use protective apparel products for the industrial, clean room, medical and dental markets. Alpha ProTech Engineered Products, Inc. manufactures and markets a line of construction weatherization products, including building wrap and roof underlayment. The Company has manufacturing facilities in Salt Lake City, Utah; Nogales, Arizona; Valdosta, Georgia; and a joint venture in India. For more information and copies of all news releases and financials, visit Alpha Pro Tech's website at http://www.alphaprotech.com. Certain statements made in this press release constitute "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statement that may predict, forecast, indicate or imply future results, performance or achievements instead of historical facts and may be identified generally by the use of forward-looking terminology and words such as "expects," "anticipates," "estimates," "believes," "predicts," "intends," "plans," "potentially," "may," "continue," "should," "will" and words of similar meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to estimated and projected earnings, margins, costs, expenditures, cash flows, sources of capital, growth rates, customer demand and future financial and operating results are forward-looking statements. We caution investors that any such forward-looking statements are only estimates based on current information and involve risks and uncertainties that may cause actual results to differ materially from the results contained in the forward-looking statements. We cannot give assurances that any such statements will prove to be correct. Factors that could cause actual results to differ materially from those estimated by us include the risks, uncertainties and assumptions described from time to time in our public releases and reports filed with the Securities and Exchange Commission, including, but not limited to, our most recent Annual Report on Form 10-K. We also caution investors that the forward-looking information described herein represents our outlook only as of this date, and we undertake no obligation to update or revise any forward-looking statements to reflect events or developments after the date of this press release. Given these uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.


Suture selection provides an important opportunity to address a key risk factor for infection – bacterial colonization of the suture. Ethicon Plus Sutures are the only globally available sutures coated with triclosan that inhibit bacteria commonly associated with SSIs (including S. aureus, S. epidermidis, MRSA, MRSE, E. coli, and K. pneumoniae.i,ii,iii) from colonizing the suture. Ethicon first innovated the triclosan-coated suture with the introduction of Coated VICRYL® Plus Antibacterial (polyglactin 910) suture in 2003. "Triclosan-coated sutures should be considered as part of an institution's comprehensive evidence-based approach to reducing the risk of SSIs," said Charles Edmiston, PhD**, Emeritus Professor of Surgery & Former Hospital Epidemiologist at Froedtert Hospital - Medical College of Wisconsin in Milwaukee. "Ethicon Plus Sutures play an important role in reducing hospital-acquired infections, and with health care costs increasingly rising, it's now more important than ever to address the risk factors associated with SSIs." Surgical Site Infections are among the most common healthcare-associated infections (HAI) worldwide; they increase morbidity and mortality in surgical patients and represent an economic burden to healthcare systems.iv In fact, SSIs have been reported as the most common type of HAI in the U.S.,v occurring in up to 3% of all hospitalized patients.vi "Ethicon, with a 60-year legacy of innovation in surgical sutures, fully supports the CDC's updated guideline, which demonstrates their commitment to improving the quality of patient care and will ultimately help save many lives," said Liza Ovington, Franchise Medical Director for Ethicon. Ethicon Plus Sutures have been shown in vitro to inhibit bacterial colonization of the suture for seven days or more, as well as bacterial growth in a zone around the suture.iii By inhibiting bacterial colonization of the suture by pathogens commonly associated with SSIs, a key risk factor for infection is addressed. Numerous peer reviewed, randomized clinical trials, as well as prospectively planned meta-analyses of these trials, support a growing body of evidence that antibacterial sutures are an important tool in the fight against surgical site infections. To learn more about Ethicon Plus Sutures, visit www.ethicon.com About Ethicon  From creating the first sutures to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world's most pressing health care issues, and improve and save more lives. Through Ethicon's surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treating serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon. *Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. Ethicon, Inc. is the legal manufacturer of Plus Antibacterial Sutures. i Ming X, Rothenburger S, Nichols MM. In vivo and in vitro antibacterial efficacy of PDS Plus (polidioxanone with triclosan) suture. Surg Infect. 2008;9(4):451-457. ii Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of Monocryl Plus Antibacterial Suture (poligelcaprone 25 with triclosan). Surg Infect. 2007;8(2):201-207. iii Rothenburger S, Spangler D, Bhende S, Burkley D. In vitro antimicrobial evaluation of coated Vicryl Plus Antibacterial Suture (coated polyglactin 910 with triclosan) using zone of inhibition assays. Surg Infect. 2002;3(suppl):79-87. iv Wang ZX, Jiang CP, Cao Y, Ding YT. Systematic review and meta-analysis of triclosan-coated sutures for the inhibition of surgical-site infection. Br J Surg. 2013;100(4):465-473. v Magill, S.S., et al., "Prevalence of healthcare-associated infections in acute care hospitals in Jacksonville, Florida". Infection Control Hospital Epidemiology, 33(3):(2012): 283-91. Accessed April 6, 2016 at http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf. vi FAQs About Surgical Site Infections. Accessed April 6, 2016: http://www.cdc.gov/HAI/pdfs/ssi/SSI_tagged.pdf. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-centers-for-disease-control-and-prevention-updated-guideline-now-include-a-recommendation-for-triclosan-coated-sutures-300454736.html


News Article | May 10, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference. “Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.” Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier. Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings. “Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1 Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


News Article | May 10, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference. “Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.” Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier. Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings. “Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1 Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


News Article | May 10, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference. “Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.” Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier. Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings. “Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1 Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


News Article | May 10, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference. “Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.” Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier. Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings. “Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1 Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


News Article | May 10, 2017
Site: globenewswire.com

BETHLEHEM, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference. “Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.” Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier. Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings. “Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1 Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.


News Article | May 12, 2017
Site: www.prweb.com

The Caregiverlist® California 10- Hour Senior Caregiver Training Course fulfills all required first year training outlined in Article 8. 1796.44 of California’s Home Care Consumer Protection Act. California caregiver training includes five hours of orientation and safety training prior to working with a client, along with five hours of annual core competency training and can be completed through an online training course. Effective January 1, 2016, new Caregivers must fulfill these 10 hours of training and 5-hour renewal training annually, all available through Caregiverlist® Caregiver Training University. Personal care aides and home health aides are in the top five fastest growing occupations in the U.S., so states have enacted training legislation to protect both the growing number of in-home care aides and the seniors they serve. Caregiverlist® Caregiver Training University provides caregivers with an online login identification and password for easy 1-click access to the training courses. Because 40% of in-home caregivers receive their certification training enrollment on their smartphones, the Caregiverlist® California 10- Hour Senior Caregiver Training Course classes are implemented to be smartphone and tablet-friendly. California caregivers receive 24/7 access to course sections, tip sheets, and quizzes that are easy to use and understand. The digital format allows caregivers to study at their own pace, on their own schedule. After finishing the course, senior caregivers may take the 36-question exam to confirm retention of the information and must score 75% to pass. They may retake the exam if needed, at no extra charge, and receive a new set of questions. Upon successful exam completion, caregivers are awarded a certificate in recognition for passing each Caregiverlist® Caregiver Training University course. Caregivers may print a wallet card size or full-size certificate for framing, or share digitally with a prospective employer. The Caregiverlist® California 10-Hour Senior Caregiver Training Course includes: Caregiver Job Responsibilities and Protocol Senior Caregiver Job Description CARE PLAN and CARE PLAN Notes and ACTIVITIES Basic Hygiene and Basic Infection Control Maintaining a Clean, Safe and Healthy Environment Basic Personal and Environmental Safety Precautions Emergency Procedures, Including Basic First Aid and CLient’s Emergency Preparedness Plan Confidentiality of Client Personal, Financial and Health Information HIPAA Communication Skills Understanding Abuse and Neglect Personal Care and Toileting Adaptive Equipment for Transfers (Gait Belts and Lifts) Also included with the online training course: ​​Glossary of Caregiver Terminology Sample Daily Care Plan Notes Audio of Course Online and Telephone support Online Quiz (sample quiz) Certificate Documenting Date of Completion and Exam Score “I finished the course and passed the exam with a 97% score. Thank you for allowing me to take the online course from my smartphone as this was very convenient for my schedule. And I really like the certificate with my name on it, too!”--Martha Gonzalez Professional caregivers may purchase the course online for $59 and senior care companies may purchase bundles of training class passes to train their caregiver employees on their own customized portal. In addition to professional caregivers, California family caregivers may also acquire training as the need for in-home caregivers increases. About Caregiverlist® Caregiverlist® is a provider of digital tools created by experienced senior home care experts. Caregiverlist® first offered caregiver certification training in 2012, applying digital tools to caregiver training customized for the senior caregiver caring for seniors in their own homes. Caregiver Training University powers the caregiver training, customized for individual state requirements. Caregiverlist® also delivers the efficiencies of the internet to senior care companies by providing online job applications, digital caregiver training portals and client referrals. Seniors and caregivers can access senior service information “by state,” view nursing home costs and star-ratings and learn about all senior care options and quality standards. For more information, please visit http://www.caregiverlist.com.


BEVERLY HILLS, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (TOMI) (OTCQX:TOMZ), a global bacteria decontamination and infection prevention company, and its board of directors announced the formation and approval of  TOMI’s scientific advisory board. “We are honored William, Miguel and Helene – experts in intellectual property law, biosafety and infection prevention, respectively – have agreed to join our scientific advisory board,” stated Dr. Halden Shane, TOMI’s Chief Executive Officer. “We believe their support validates TOMI’s groundbreaking SteraMist™, and their guidance will help TOMI in "Innovating for a Safer World.” The team is charged with constructively challenging management to help develop strategy; ensuring the necessary resources are in place to enable us to achieve objectives in scientific research and development; and monitoring technological and regulatory trends that could impact our business as well as our performance against our goals. We believe their insight will be invaluable.” William M. Brown, PhD, MBA, JD William M. Brown, PhD, MBA, JD is a consultant and advisor to a series of biotech and life sciences companies. Dr. Brown is a seasoned attorney in intellectual property with deep experience in healthcare-related matters. He is licensed to practice law in several states and is a registered patent attorney. His consulting experience includes intellectual property portfolio management, clinical trial contracts, and patent/business development matters. He holds a PhD from the University of Southampton, England, an MBA from Fairleigh Dickinson University, and a JD from New York Law School. Dr. Brown conducted postdoctoral research at Harvard, Johnson & Johnson, NIH, and Memorial Sloan-Kettering Cancer Center. Miguel A. Grimaldo, MEng Miguel A. Grimaldo, MEng is an Assistant Professor for the Department of Pathology, Director of Institutional Biocontainment Resources at the University of Texas Medical Branch (UTMB) and the Director of the Biocontainment Engineering Division for the Galveston National Laboratory. His responsibilities include the review of all design, construction, commissioning and operation of High and Maximum containment laboratories as well as to ensure regulatory compliance and to conduct ongoing evaluation and recertification on all critical containment features, equipment and operations for Biosafety Level 3 (BSL‐3), Animal Biosafety Level 3 (ABSL3) and Biosafety Level 4 (BSL4) laboratory facilities at UTMB. He is also a member of the UTMB Institutional Biosafety Committee. He has served as Committee Member for development of the ANSI Z9.14‐2014 Standard ‐ Testing and Performance‐Verification Methodologies for Ventilation Systems for Biosafety Level 3 (BSL‐3) and Animal Biosafety Level 3 (ABSL‐3) facilities as well as for the 2016 Edition of the National Institute of Health (NIH) ‐ Design Requirements Manual (DRM) for Biomedical Laboratories and Animal Research Facilities. Miguel routinely serves as Biocontainment Advisor for containment laboratories nationally and internationally on design, construction and operations and also routinely contributes to a technical column in the American Biological Safety Association (ABSA) journal, Applied Biosafety entitled, “Containment Talk”. Mr. Grimaldo obtained his Masters of Engineering from the University of Louisville and Bachelor of Science degrees in Agricultural Engineering and Agricultural Economics from Texas A&M University. Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC, is an Infection Preventionist, owner of Bio Guidance, LLC, adjunct biology professor at Rowan University and Director of Infection Prevention at Saint Francis Healthcare. She is Infection Control Certified (CIC), board certified as an International Medical Laboratory Scientist and holds a PhD in Epidemiology. Dr. Paxton has 40 plus years’ experience in medical devices and infectious disease consulting. Dr. Paxton obtained her PhD from Kennedy Western University and her MS from Bowling Green State University. Scientific Advisory Board Provisions and criteria have been set in the company's bylaws and scientific advisory board charter. TOMI’s scientific advisory board will always observe in the letter and spirit the duties, rights and role as a member of the company's board as stipulated in the relevant listing standards. About TOMI™ Environmental Solutions, Inc. TOMI™ Environmental Solutions, Inc. (OTCQX:TOMZ) is a global bacteria decontamination and infectious disease control company, providing eco-friendly environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier platform of Hydrogen Peroxide based product that uses Binary Ionization Technology® (BIT™) , a state of the art technology for the production of its Activated Ionized Hydrogen Peroxide mist represented by the TOMI™ SteraMist™ brand. TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences. TOMI also develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association. For additional product information, visit www.tomimist.com or contact us at info@tomimist.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.


SINGAPORE, Feb. 14, 2017 /PRNewswire/ -- During the 8th International congress of the Asia Pacific Society of Infection Control (APSIC) in Bangkok, Thailand, leading healthcare company, Mundipharma, will be sponsoring medical educational programs with an international panel to discuss solutions and initiatives to tackle challenges in antimicrobial resistance as well as the importance of proper hygiene practices. At the Congress, Mundipharma will share evidence about how BETADINE® medicines that contain PVPI can be used as a virucide against seasonal infections such as flu, as well as help to prevent infectious disease outbreaks such as MERS, SARS, Ebola, HFMD (Hand Foot and Mouth Disease) and Norovirus in both public and hospital settings. The positive results generated by a leading virologist on PVPI's role against tough to kill viruses and its role in public health will also be presented. In addition, Mundipharma will showcase a digital app as part of its support of the objectives outlined in the WHO's Global Action Plan on Antimicrobial Resistance to improve hygiene measures, reduce infection and limit the use of antibiotics. "Recent global viral outbreaks and the challenges presented by nosocomial infections demonstrate the critical importance of infection control in the race to limit the spread of infections," said Raman Singh, President Mundipharma Asia Pacific, Latin America the Middle East & Africa. "The live demonstration will include an exchange with infection control experts on how digital solutions can drive better hygiene practices to reduce infections and limit the use of antibiotics. In today's highly digitalized world, the app will be a game changer as it will be able to be shared, downloaded and used faster than diseases can spread." "Mundipharma brings to the congress a team of independent experts with deep experience in infection control. They will discuss the appropriate use of antiseptics, antibiotics and hygiene interventions that limit the spread of resistant microorganisms and reduce antimicrobial misuse and overuse, as well as a perspective on the targeted hygiene concept -- aimed at implementing a risk-based approach to hygiene. Mundipharma's independent associated companies are privately owned entities covering the world's pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. The Asia Pacific Society of Infection Control (APSIC) was established in 1998 and is a multi-national, voluntary, organization dedicated to the advancement of infection control practice to reduce hospital associated infections, monitor and control emerging and re-emerging infectious diseases and improved patient outcomes. APSIC brings together multidisciplinary infection control professionals in the region to share their knowledge, experience, skills, and quality improvement and research findings by facilitating the exchange of information through training courses, seminars, congresses and conferences in the Asia Pacific region. Registered indications differ country to country hence please check with a local Mundipharma office for more information on the local approved prescribing information.

Loading Infection Control collaborators
Loading Infection Control collaborators